Reviewing Cellectar Biosciences Inc. (CLRB)’s and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s results

Cellectar Biosciences Inc. (NASDAQ:CLRB) and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) compete with each other in the Biotechnology sector. We will analyze and contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellectar Biosciences Inc. N/A 0.00 17.18M -8.63 0.00
Vanda Pharmaceuticals Inc. 184.35M 5.12 13.01M 0.24 119.96

Table 1 highlights Cellectar Biosciences Inc. and Vanda Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 represents Cellectar Biosciences Inc. (NASDAQ:CLRB) and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Cellectar Biosciences Inc. 0.00% -198.4% -140.3%
Vanda Pharmaceuticals Inc. 7.06% 5.9% 4.6%

Risk and Volatility

A 0.55 beta means Cellectar Biosciences Inc.’s volatility is 45.00% less than Standard and Poor’s 500’s volatility. Competitively, Vanda Pharmaceuticals Inc.’s beta is 0.74 which is 26.00% less volatile than Standard and Poor’s 500.

Liquidity

Cellectar Biosciences Inc. has a Current Ratio of 6.4 and a Quick Ratio of 6.4. Competitively, Vanda Pharmaceuticals Inc.’s Current Ratio is 6 and has 6 Quick Ratio. Cellectar Biosciences Inc.’s better ability to pay short and long-term obligations than Vanda Pharmaceuticals Inc.

Analyst Recommendations

The Recommendations and Ratings for Cellectar Biosciences Inc. and Vanda Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cellectar Biosciences Inc. 0 0 0 0.00
Vanda Pharmaceuticals Inc. 0 2 4 2.67

Competitively the consensus target price of Vanda Pharmaceuticals Inc. is $40.17, which is potential 123.17% upside.

Institutional & Insider Ownership

Cellectar Biosciences Inc. and Vanda Pharmaceuticals Inc. has shares held by institutional investors as follows: 11.7% and 99.85%. Insiders held roughly 0.6% of Cellectar Biosciences Inc.’s shares. Competitively, insiders own roughly 0.2% of Vanda Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cellectar Biosciences Inc. -1.79% -15.77% -7.98% -78.32% -82.76% -84.01%
Vanda Pharmaceuticals Inc. 14.5% 40.2% 57.1% 58.4% 106.26% 88.62%

For the past year Cellectar Biosciences Inc. has -84.01% weaker performance while Vanda Pharmaceuticals Inc. has 88.62% stronger performance.

Summary

On 10 of the 11 factors Vanda Pharmaceuticals Inc. beats Cellectar Biosciences Inc.

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company offers CLR 131, a PDC cytotoxic radioisotope product candidate, which is in Phase I clinical study for the treatment of relapse or refractory multiple myeloma, as well as in Phase II clinical study for the treatment of B-cell malignancies; and CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease. It also provides CLR 124, a cancer-targeting positron emission tomography imaging PDC for the selective detection of tumors and metastases in a range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. In addition, the company is developing CLR 1601-PTX, CLR 1602-PTX, and CLR 1603-PTX product candidates, which are in pre-clinical research for the treatment of chemotherapy. It has strategic collaboration with Onconova Therapeutics, Inc. to develop phospholipid drug conjugates. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companyÂ’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.